smithkline &lt;skb> aims 10 pct earnings raise smithkline beckman corp pursuing three-point stragey achieve 10 pct annual increase operating earnings remainder decade. 1986, smithkline earned 521.1 mln dlrs 6.78 dlrs share revenues 3.6 billion dlrs. company annual report nonpharmaceutical business play major role meeting earnings growth target, fact grow faster pharmaceutical business. smithkline, major product antiulcer medication tagamet, report intends improve earnings existing products, expand product portfolio optimize financial resources. bolster position antiulcer market, tagamet met stiff competition, smithkline strategy develop over-the-counter version tagamet bolstered joint ventures, &lt;wellcome plc>, pending venture japan. smithkline allergan eye skin care products division billion dlr organization years grow 10 pct annually. "nondilutive acquisitions real possibility," gavin herbert, president eye skin care product group report. 1986, allergan worldwide sales 433 mln dlrs. smith kline french laboratories pharmaceuticals unit, 1986 sales 1.9 billion dlrs, file food drug administration marketing approval number cardiovascular agents, including tissue plasminogen activator, years. sk f's u.s. sales force 20 pct larger 1987, 1,000 sales personnel. smith kline small clinical laboratory testing unit, 1986 sales 373 mln dlrs, performs 24 mln tests year, sees increases employee drug testing testing aids antibody. smith kline depending share price cost money, buy back shares. years, bought back 25 pct shares. smithkline begins year management team, including chief operating officer george ebright.